<html>
<head>
<title>Corporate bio VCs are backing more rounds and making bigger bets • TechCrunch</title>
<link href="../Styles/Style.css" type="text/css" rel="stylesheet"/>
</head>
<body>
<h1 class="translated">企业生物风险投资公司正在支持更多的轮次和更大的赌注TechCrunch</h1>
<blockquote>原文：<a href="https://web.archive.org/web/https://techcrunch.com/2018/03/10/corporate-bio-vcs-are-backing-more-rounds-and-making-bigger-bets/?ncid=rss">https://web.archive.org/web/https://techcrunch.com/2018/03/10/corporate-bio-vcs-are-backing-more-rounds-and-making-bigger-bets/?ncid=rss</a></blockquote><div><div class="article-content">
				<p id="speakable-summary">
</p><div class="article__contributor-byline">
	<div class="contributor-byline__contributor">
		<p class="byline__author translated"><span class="byline__author-name">乔安娜·格拉斯纳</span><span class="byline__author-title">撰稿人</span></p>

			</div>

		
	
		<div class="contributor-byline__more-articles">
		<span class="more-articles-title">More posts by this contributor</span>
		
	</div>
	</div>

<p class="translated"><span class="dropcap"> B </span> iotech很像风险投资。大量的研究、测试和营销进入了广泛的治疗领域。但最终，只有极少数人获得了大部分回报。</p>
<p class="translated">这种相似性可能是为什么大多数最大的生物技术和制药公司都有着作为创业投资者、衍生创造者和战略合作伙伴参与风险业务的悠久历史。根据Crunchbase的数据，自去年以来，最大的企业参与者参与了价值超过64亿美元的融资。趋势线还显示投资正在上升。</p>
<p class="translated">为了衡量这个创业融资空间的规模、范围和增长轨迹，Crunchbase News收集了一些生物技术领域最大的企业风险投资者的数据集。我们筛选出市值最大的公司，并筛选出19家有积极融资历史的公司，通常是通过专门的风险部门。</p>
<p class="translated">纵观这些企业投资者，我们发现交易数量在2017年达到了十年来的最高点。平均回合规模也在变大，所以看起来企业生物风投也在投入更多资金。以下是我们的一些更详细的发现。</p>
<h2 class="translated">回合数上升了，而且越来越大</h2>
<p class="translated">在整个风险行业，平均每一轮的规模都在变大。因此，企业生物投资者跟风也就不足为奇了。</p>
<p class="translated">去年，我们候选名单上的风投参与了117轮融资，总计价值52亿美元。这相当于平均每轮4400万美元——是过去五年中最高的平均水平。</p>
<p class="translated">但是圆形尺寸可能还有更高的价格。到目前为止，2018年是一个昂贵的开始，平均轮次规模超过6000万美元，这要归功于最近为胎盘干细胞领域的<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/celularity" target="_blank" rel="noopener"> Celularity </a>和个人基因组分析提供商<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/helix" target="_blank" rel="noopener"> Helix </a>提供的超过2亿美元的融资。</p>
<p class="translated">下面，我们来看看入围的公司生物投资者每年的投资轮数，以及所有支持者在这些轮中的投资总额。</p>
<p class="translated"><img decoding="async" class="alignnone wp-image-1605099 size-large" src="../Images/81b4d0340f22960b4fecbe867b0baf5a.png" alt="" srcset="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png 1024w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=150,148 150w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=300,297 300w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=768,760 768w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=680,673 680w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=32,32 32w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=50,50 50w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=64,64 64w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=96,96 96w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?resize=128,128 128w" sizes="(max-width: 680px) 100vw, 680px" data-original-src="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-one-joanna.png?w=680"/></p>
<p> </p>
<h2 class="translated">企业生物风投也在引领更多轮投资</h2>
<p class="translated">当有一个大财团的共同投资者时，很难判断一个投资者在一轮投资中投入了多少。这就是为什么我们也特别关注与作为主要投资者的公司生物风险投资的交易，因为这意味着大量的股份。</p>
<p class="translated">在过去的五个日历年里，最活跃的企业生物投资者每年集体领先28至40轮，2017年的总数最高。然而，以企业生物风险投资为主要投资者的资本总额在2016年达到了多年来的最高水平，投资了约14亿美元。</p>
<p class="translated">在下图中，我们查看了过去五个日历年以及2018年前几个月的领先轮次:</p>
<p class="translated"><img decoding="async" loading="lazy" class="alignnone wp-image-1605096 size-large" src="../Images/a0fa6d5839781d8e98b0bdc0341b346a.png" alt="" srcset="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png 1024w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=150,150 150w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=300,297 300w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=768,761 768w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=680,674 680w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=32,32 32w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=50,50 50w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=64,64 64w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=96,96 96w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?resize=128,128 128w" sizes="(max-width: 680px) 100vw, 680px" data-original-src="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-2-joanna.png?w=680"/></p>
<p> </p>
<p class="translated">几轮真正的大投资会影响投资总额。例如，今年，总额中的2 . 5亿美元来自一笔交易:由Celgene牵头的对前述<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/celularity" target="_blank" rel="noopener"> Celularity </a>的投资，这是一家专注于胎盘干细胞疗法的分拆公司。去年，总额中的1.5亿美元来自Biogen公司为免疫疗法开发商<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/neurimmune-holding#section-overview" target="_blank" rel="noopener"> Neurimmune </a>牵头的一轮融资。</p>
<h3 class="translated">谁最活跃</h3>
<p class="translated">正如人们所料，生物技术和制药领域最活跃的企业风险投资者都是该领域估值最高的上市公司。这些公司不仅资金雄厚，而且还不断受到股东的压力，要求它们开发突破性疗法并将其商业化。虽然这可以在内部完成，但主要参与者意识到，在创业空间中拥有一些皮肤也是必要的。</p>
<p class="translated">在下图中，我们看到了过去五年中最活跃的公司生物投资者。他们的大部分交易来自专项风险基金，其中大多数已经存在多年。</p>
<p class="translated"><img decoding="async" loading="lazy" class="alignnone wp-image-1605097 size-large" src="../Images/a73ba67749c3e98dc5f4968413476ac0.png" alt="" srcset="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png 1024w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png?resize=150,109 150w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png?resize=300,219 300w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png?resize=768,560 768w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png?resize=680,495 680w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png?resize=50,36 50w" sizes="(max-width: 680px) 100vw, 680px" data-original-src="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-3.png?w=680"/></p>
<h3 class="translated"><img decoding="async" loading="lazy" class="alignnone wp-image-1605098 size-large" src="../Images/674b0da7adf9ffbcc08245d3d4c86986.png" alt="" srcset="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png 1024w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png?resize=150,109 150w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png?resize=300,218 300w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png?resize=768,559 768w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png?resize=680,495 680w, https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png?resize=50,36 50w" sizes="(max-width: 680px) 100vw, 680px" data-original-src="https://web.archive.org/web/20230131000732im_/https://techcrunch.com/wp-content/uploads/2018/03/chart-joanna-4.png?w=680"/></h3>
<h3 class="translated">谁领先了？</h3>
<p class="translated">最近几个季度，一些企业风投变得越来越活跃。</p>
<p class="translated">Celgene尤其突出。总部位于新泽西州的制药巨头Summit面临扩大管道的压力，因为目前其超过一半的收入来自单一产品，即化疗药物Revlimid。</p>
<p class="translated">作为回应，Celgene在收购和风险投资交易上投入了大量资金。今年，它宣布计划以高达70亿美元的交易收购风险投资支持的药物开发商<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/impact-biomedicines" target="_blank" rel="noopener"> Impact Biomedicines </a>，并以90亿美元收购公开交易的癌症免疫疗法开发商<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/juno-therapeutics" target="_blank" rel="noopener"> Juno Therapeutics </a>。至于风险交易，除了上个月支持Celularity之外，Celgene还刚刚为药物开发商<a href="https://web.archive.org/web/20230131000732/https://www.crunchbase.com/organization/vividion-therapeutics" target="_blank" rel="noopener"> Vividion Therapeutics </a>领投了1亿美元的融资。</p>
<p class="translated">Crunchbase数据显示，强生公司和艾伯维公司在过去几个季度也一直在加快投资步伐。</p>
<h3 class="translated">向出口前进</h3>
<p class="translated">对有前途的生物技术创业公司来说，相当强劲的IPO市场在一定程度上抵消了企业生物风投的风险。在过去的四个月里，在美国交易所上市的医疗保健IPO实际上超过了科技公司。</p>
<p class="translated">如果首次公开募股是不可能的，总是有选择购买公司本身或允许竞争对手抢购他们。</p>
			</div>

			</div>    
</body>
</html>